132 related articles for article (PubMed ID: 20118061)
1. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
Aleem A
Hematol Oncol Stem Cell Ther; 2009; 2(2):358-61. PubMed ID: 20118061
[TBL] [Abstract][Full Text] [Related]
2. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate induced skin hypopigmentation.
Talwar V; Doval DC; Bhatia K
J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
[No Abstract] [Full Text] [Related]
5. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Medhi K; Raina V; Kumar L; Sharma A; Bakhshi S; Gupta R; Kumar R
Leuk Lymphoma; 2010 Oct; 51(10):1850-4. PubMed ID: 20849386
[TBL] [Abstract][Full Text] [Related]
6. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
Raanani P; Goldman JM; Ben-Bassat I
J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
[No Abstract] [Full Text] [Related]
7. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
Department of Medical and Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat. INDIA
Gulf J Oncolog; 2017 Jan; 1(23):15-20. PubMed ID: 28271997
[TBL] [Abstract][Full Text] [Related]
9. Hypopigmentation from imatinib mesylate (Gleevec).
Grossman WJ; Wilson DB
J Pediatr Hematol Oncol; 2004 Mar; 26(3):214. PubMed ID: 15125619
[No Abstract] [Full Text] [Related]
10. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
Charles KS; Ramon L; Leelah N; Oluwabusi TA; Seemungal T
West Indian Med J; 2011 Jun; 60(3):298-302. PubMed ID: 22224342
[TBL] [Abstract][Full Text] [Related]
11. Hypopigmentation in an African patient treated with imatinib mesylate: a case report.
Hasan S; Dinh K; Lombardo F; Dawkins F; Kark J
J Natl Med Assoc; 2003 Aug; 95(8):722-4. PubMed ID: 12934870
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population.
Zhao Y; Liu L; Wang Y; Wu G; Lai X; Cao W; Luo Y; Tan Y; Shi J; Xie W; Ye X; Cai Z; Lin M; Huang H
Int J Hematol; 2009 May; 89(4):445-451. PubMed ID: 19350352
[TBL] [Abstract][Full Text] [Related]
15. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
16. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
[TBL] [Abstract][Full Text] [Related]
17. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate causes hypopigmentation in the skin.
Leong KW; Lee TC; Goh AS
Cancer; 2004 Jun; 100(11):2486-7; author reply 2487-8. PubMed ID: 15160360
[No Abstract] [Full Text] [Related]
19. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
20. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
